Functional Movement DisorderNCT06439017
Passive Thoughts in Functional Movement Disorders
An observational study of Functional Movement Disorder, run by Western University, Canada at 1 site in Canada.
Trial summary
Passive thoughts also known as mind-wandering are the thoughts that are not produced from the current task. When we aren't focused on a task that needs our full attention, our minds tend to drift from one thought to another. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Functional Movement Disorder
- What is being tested?
- Questionaire
- How many people
- 60 participants
- Where
- 1 siteCanada
- Study dates
- Mar 2025to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients diagnosed with a functional movement disorder will be included in the study.
Who may be able to join
- Diagnosed with a functional movement disorder by the neurologist.
- Able to understand and read English.
Who cannot join
- Unable to understand and read English.
- Diagnosed with dementia.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Passive thoughts also known as mind-wandering are the thoughts that are not produced from the current task. When we aren't focused on a task that needs our full attention, our minds tend to drift from one thought to another. It is believed that mind wandering is the baseline or natural state of the mind, and we shift our focus only when needed for a task. Many areas of the brain are active during mind-wandering, and these areas together are called the brain's default network. An important part of this network is the right temporoparietal junction.
Functional movement disorder (FMD) is characterized by unusual movements or walking difficulties that are not caused by a specific brain or nerve injury. Functional movement disorders are believed to be caused due to loss of sense of agency. The sense of agency is the awareness that one is responsible for their own actions. The brain network involved in the sense of agency is mainly located in the right side of the brain, especially in the right temporoparietal junction. In FMD patients, there is decreased connectivity between the right temporoparietal junction and other brain areas that control movement.
Since both passive thoughts (mind wandering) and the sense of agency involve the temporoparietal junction, and because the sense of agency is abnormal in functional movement disorders (FMD), we plan to study passive thoughts in individuals with FMD. The study aims to find out how passive thoughts differ between individuals with FMD and healthy individuals. Passive thoughts will be measured using Mind Excessively Wandering Scale (MEWS).
Read the detailed description
To evaluate passive thoughts in functional movement disorders (FMD), we will collect data from 30 FMD patients and 30 healthy controls. Patients will be recruited from the movement disorders clinic and the integrated functional movement disorders clinic at LHSC. Both groups will be asked to complete the paper-based Mind Excessively Wandering Scale (MEWS) to evaluate passive thoughts. Additionally, FMD patients will complete the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire designed to measure disability over the past 30 days. Completing both questionnaires will take approximately 15-20 minutes. The questionnaires will be completed once.
- Conditions
- Functional Movement Disorder
- Being tested
- Questionaire
- Medical subject headings
- Conversion Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionaireOther
The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
| Study group | Role | What they receive |
|---|---|---|
| Cases with functional movement disorders | The cases will complete the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire. The individual responses will remain anonymous. Receives: Other: Questionaire | |
| Healthy controls | The controls will complete the Mind Excessively Wandering Scale (MEWS). The individual responses will remain anonymous. Receives: Other: Questionaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Passive thoughts questionnaire
The Passive Thoughts Questionnaire assesses the severity of passive thoughts and their impact on daily life.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2024
- Study startMar 2025 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Functional Movement DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western University, Canada
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aditya Murgai, Western University, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06439017
- Sponsor's protocol ID
- 125294
- Status last verified
- Sep 2024
- First submitted
- 27 May 2024
- Last updated
- 24 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Passive Thoughts in Functional Movement Disorders
- ClinicalTrials.gov ID
- NCT06439017
- Acronym / sponsor ID
- 125294
- Conditions
- Functional Movement Disorder
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Western University, CanadaUniversity, hospital or other
- Study start
- Mar 2025 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 3 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Passive thoughts also known as mind-wandering are the thoughts that are not produced from the current task. When we aren't focused on a task that needs our full attention, our minds tend to drift from one thought to another. It is believed that mind wandering is the baseline or natural state of the mind, and we shift our focus only when needed for a task. Many areas of the brain are active during mind-wandering, and these areas together are called the brain's default network. An important part of this network is the right temporoparietal junction.
Functional movement disorder (FMD) is characterized by unusual movements or walking difficulties that are not caused by a specific brain or nerve injury. Functional movement disorders are believed to be caused due to loss of sense of agency. The sense of agency is the awareness that one is responsible for their own actions. The brain network involved in the sense of agency is mainly located in the right side of the brain, especially in the right temporoparietal junction. In FMD patients, there is decreased connectivity between the right temporoparietal junction and other brain areas that control movement.
Since both passive thoughts (mind wandering) and the sense of agency involve the temporoparietal junction, and because the sense of agency is abnormal in functional movement disorders (FMD), we plan to study passive thoughts in individuals with FMD. The study aims to find out how passive thoughts differ between individuals with FMD and healthy individuals. Passive thoughts will be measured using Mind Excessively Wandering Scale (MEWS).
Detailed description
To evaluate passive thoughts in functional movement disorders (FMD), we will collect data from 30 FMD patients and 30 healthy controls. Patients will be recruited from the movement disorders clinic and the integrated functional movement disorders clinic at LHSC. Both groups will be asked to complete the paper-based Mind Excessively Wandering Scale (MEWS) to evaluate passive thoughts. Additionally, FMD patients will complete the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire designed to measure disability over the past 30 days. Completing both questionnaires will take approximately 15-20 minutes. The questionnaires will be completed once.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases with functional movement disorders | – | Other: QuestionaireThe cases will complete the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire. The individual responses will remain anonymous. |
| Healthy controls | – | Other: QuestionaireThe controls will complete the Mind Excessively Wandering Scale (MEWS). The individual responses will remain anonymous. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with a functional movement disorder will be included in the study.
Key inclusion criteria (2 listed)
- Diagnosed with a functional movement disorder by the neurologist.
- Able to understand and read English.
Key exclusion criteria (2 listed)
- Unable to understand and read English.
- Diagnosed with dementia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionaireThe study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire. | Other | Cases with functional movement disorders, Healthy controls |
Primary outcome
Passive thoughts questionnaire
Time frame: Day 1
The Passive Thoughts Questionnaire assesses the severity of passive thoughts and their impact on daily life.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Functional Movement Disorder
Recruiting
Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodies
Photobiomodulation, Dementia With Lewy Bodies
Recruiting
SMAdult - Monitoring of Movement on Spinal Muscular Atrophy
Spinal Amyotrophy
RecruitingPhase 2
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
Parkinson's Disease
Recruiting
Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
REM Sleep Behavior Disorder, Parkinson s Disease
Recruiting
EXercise-induced PhysioLogical Adaptations In Neurological Disorders
Epilepsy, Functional Neurological Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Functional Movement Disorder, run by Western University, Canada at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Passive thoughts questionnaire (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2025.